Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
- Guideline Contact
- [email protected]
- Publication Date
- 13-Apr-22
- Countries of Application
- United States
- Languages
- English
- Authors
- ASCO (US)
- Publication Year
- 2022
Stomach Neoplasms (C04.588.274.476.767); Chemotherapy; Adjuvant (E02.186.170); Neoadjuvant Therapy (E02.186.450); Radiotherapy; Adjuvant (E02.186.775); Meta-Analysis as Topic (E05.581.500.501); Review Literature as Topic (L01.178.682.759)
Renal Insufficiency; Chronic (C13.351.968.419.780.750); Renal Insufficiency; Chronic (C12.777.419.780.750); Kidney Failure; Chronic (C12.777.419.780.750.500); Kidney Failure; Chronic (C13.351.968.419.780.750.500)
Purpura; Thrombocytopenic (C23.550.414.950.687); Purpura; Thrombocytopenic (C20.841); Purpura; Thrombocytopenic (C23.888.885.687.687); Purpura; Thrombocytopenic (C15.378.100.802.687); Purpura; Thrombocytopenic (C15.378.140.855.925.750)
Infant; Newborn (M01.060.703.520); Infant; Newborn; Diseases (C16.614)